DENN polyclonal antibody has been described(Zhang, Y., Zhou, L. & Miller, C. A. (1998) Proc. Natl. Acad. Sci. USA 95, 2586–2591).
Following antibodies were used in this study: JNK3 and phospho-c-Jun (Upstate Biotechnology, 1:1,000 and 1:200, respectively);
TRADD, FADD, and RIP (BD Pharmingen; 1:250, 1:200, and 1:1,000, respectively);
TNFR1 (sc-8436), TRAF2 (sc-7346), and JNK1 (FL) (sc-571) (Santa Cruz Biotechnology; 1:100, 1:200, and 1:1,000, respectively);
phospho-JNK and Myc (Cell Signaling Technology, 1:500 and 1:1,000, respectively);
GFP (BD Clontech; 1:2,000);
MAP2, b-actin, and NF200 (Sigma; 1:2,000, 1:1,000, and 1:500, respectively);
monoclonal AT8 (Endogen, 1:1,000);
and monoclonal 22C11, which recognizes the Ab region of APP (Chemicon; 1:1,000).